MarketWatch -- Basilea Pharmaceutica AG, the Basel drugmaker, said on Thursday that a Johnson & Johnson subsidiary asked the European Committee For Medicinal Products for Human Use to re-examine its rejection of ceftobiprole to treat complicated skin and soft-tissue infections.
